Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do. Our investigational product, HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver, while controlling systemic exposure and associated side effects. We have the potential to change the lives of people with rare and life-threatening cancers of the liver with an innovative approach to drug-delivery. To date, over 1,000 treatments in Europe have been conducted, in both the commercial and clinical setting.